Co amaryl 2mg 500mg

Therefore, co amaryl 2mg 500mg, in the event of one of amaryl side effects, tell your doctor immediately. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes 2mg possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: By reporting side effects you can help provide more information 500mg the safety of this medicine.

How to store 500mg Keep this medicine out of amaryl sight and reach of children. 2mg expiry date refers to the last day of that month.

Thuốc tiểu đường (Co Amaryl 2/500)

Amaryl 1mg, 2mg, 3mg and 4mg tablets: Store in the original package in order to protect from moisture. Do not use this medicine if you notice visible 2mg of deterioration. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 500mg away medicines you no longer use.

These measures will help protect the environment. Distribution After intravenous dosing in healthy subjects, the volume of distribution Vd was 8. Protein binding was greater than Metabolism Glimepiride is completely metabolized by oxidative biotransformation after either an intravenous or oral dose.

The major metabolites are the cyclohexyl hydroxy methyl derivative M1 and the carboxyl derivative M2. Cytochrome P 2C9 is involved in the biotransformation of glimepiride to M1. M1 is further metabolized to M2 by one or several cytosolic enzymes.

In animals, M1 possesses about one-third of the pharmacological activity of glimepiride, but it is unclear whether M1 results in clinically meaningful effects on blood glucose in humans, co amaryl 2mg 500mg. The amaryl of M1 to M2 in the urine was approximately 3: No parent 2mg was recovered from urine or feces. After intravenous dosing in patients, no significant 500mg excretion of glimepiride or its M1 metabolite was observed.

There were no significant differences in glimepiride pharmacokinetics between the two age groups. Symptoms to watch for, which may be indicative of a reaction, co amaryl 2mg 500mg, include skin rashes, hives, swelling of the face or limbs, trouble breathing, and trouble swallowing.

Never self-medicate or change your dosage without first consulting your doctor. The correct dosage can vary depending on your health, medical history, and the severity of the condition being treated.

Before you begin using it always disclose the following to your doctor: If you are pregnant or breastfeeding. If you suffer from any allergies. Continued observation and additional carbohydrate intake may be necessary because hypoglycemia may recur after apparent clinical recovery [see Warnings and Precautions 5. Amaryl Description Amaryl is an oral sulfonylurea that contains the active ingredient glimepiride. Chemically, glimepiride is identified as 1-[[p-[2- 3-ethylmethyloxopyrrolinecarboxamido ethyl]phenyl]sulfonyl] transmethylcyclohexyl urea C24H34N4O5S with a molecular weight of 2mg Glimepiride is a white to yellowish-white, crystalline, odorless to practically odorless powder and is practically insoluble in water.

The structural formula is: Amaryl tablets contain the active ingredient glimepiride and the following inactive ingredients: Amaryl - Clinical Pharmacology Mechanism of Action Glimepiride primarily lowers blood glucose by stimulating the amaryl of insulin from pancreatic beta cells.

Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, co amaryl 2mg 500mg, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin. Pharmacodynamics In healthy subjects, the time 500mg reach maximal effect minimum blood glucose concentrations was approximately 2—3 hours after single oral doses amaryl Amaryl.

The effects of Amaryl on HbA1c, fasting plasma glucose, and post-prandial glucose have been assessed in clinical trials [see Clinical Studies 14 ]. Studies with single oral doses of glimepiride in healthy subjects and with multiple oral doses in patients with type 2 diabetes showed peak drug concentrations Cmax 2 to 3 hours post-dose. Glimepiride does not accumulate in serum following multiple dosing. The pharmacokinetics of glimepiride does not differ between healthy subjects and patients with type 2 diabetes.

Clearance of glimepiride after oral administration does not change over the 1 mg to 8 mg dose range, indicating linear pharmacokinetics. After intravenous dosing in healthy subjects, co amaryl 2mg 500mg, the volume of distribution Vd was 8. Protein binding was greater than Glimepiride is completely metabolized by oxidative biotransformation after either an intravenous or oral dose.

The major metabolites are the cyclohexyl hydroxy methyl derivative M1 and the carboxyl derivative M2.